Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

aclidinium/formoterol (Duaklir Pressair)

Initiation (new start) criteria: Non-formulary aclidinium bromide/formoterol fumarate (Duaklir Pressair) will be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium/olodaterol (Stiolto Respimat) AND one of the following medications: glycopyrrlate/formoterol (Bevespi Aerosphere), glycopyrrlate/indacaterol (Utibron NeoHaler), umeclidinium/vilanterol (Anoro Ellipta); OR patient has an allergy or intolerance* to all of the aforementioned medications.
  * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary aclidinium bromide/formoterol fumarate (Duaklir Pressair) will be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium/olodaterol (Stiolto Respimat) AND one of the following medications: glycopyrrlate/formoterol (Bevespi Aerosphere), glycopyrrlate/indacaterol (Utibron NeoHaler), umeclidinium/vilanterol (Anoro Ellipta); OR patient has an allergy or intolerance* to all of the aforementioned medications.
  * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Continued use criteria for patients stable on the medication: Non-formulary aclidinium bromide/formoterol fumarate (Duaklir Pressair) will continue to be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium/olodaterol (Stiolto Respimat) AND one of the following medications: glycopyrrlate/formoterol (Bevespi Aerosphere), glycopyrrlate/indacaterol (Utibron NeoHaler), umeclidinium/vilanterol (Anoro Ellipta); OR patient has an allergy or intolerance* to all of the aforementioned medications.
  * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation